================================================================================
COLLECTED CLINICAL TRIALS REPORT
================================================================================
Collection Date: 2025-07-22 13:46:39
Total Studies: 37
Studies with Publications: 13
Studies without Publications: 24
Search Query: AREA[Condition](Neuroendocrine Tumors OR Carcinoma Neuroendocrine OR Carcinoid Tumor) AND NOT (AREA[Phase]Phase 1) AND AREA[OverallStatus](ACTIVE_NOT_RECRUITING OR COMPLETED) AND (AREA[HasResults]true) AND AREA[PrimaryCompletionDate] RANGE[2020-01-01,MAX]
Filter Criteria: Neuroendocrine tumor studies, excluding Phase 1
--------------------------------------------------------------------------------

1. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
   NCT ID: NCT04852679
   Status: COMPLETED
   Phase: PHASE3
   Condition: Gastroenteropancreatic Neuroendocrine Tumor
   Intervention: Lanreotide autogel
   Sponsor: Ipsen
   Start Date: 2021-05-24
   Completion Date: 2023-01-13
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04852679
   Summary: This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs.

The study will include a screening period of up to 4 weeks followed by a 48-week intervention period. After comple...
   Locations: Cancer Hospital Chinese Academy of Sciences, Beijing, China; Beijing Cancer Hospital, Beijing, China; Peking University Third Hospital, Beijing, China
              ... and 11 more locations
----------------------------------------

2. Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
   NCT ID: NCT03290079
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Neuroendocrine Carcinoma; Neuroendocrine Cancer
   Intervention: Pembrolizumab; Lenvatinib
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2017-12-15
   Completion Date: 2024-05-13
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03290079
   Summary: The purpose of this study is to:

* Assess overall radiographic response rate (ORR)
* Assess progression-free survival (PFS)
* Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
   Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
----------------------------------------

3. Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
   NCT ID: NCT02318784
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Cancer
   Intervention: Carfilzomib
   Sponsor: SCRI Development Innovations, LLC
   Start Date: 2015-07-15
   Completion Date: 2021-05-15
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02318784
   Summary: The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
   Locations: Rocky Mountain Cancer Center, Denver, United States; Florida Cancer Specialists, Fort Myers, United States; Florida Hospital Cancer Institute, Orlando, United States
              ... and 7 more locations
----------------------------------------

4. Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
   NCT ID: NCT03273712
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Meningioma; Neuroblastoma; Medulloblastoma
   Intervention: 90Y-DOTA tyr3-Octreotide; 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan; Amino Acids
   Sponsor: University of Iowa
   Start Date: 2017-09-29
   Completion Date: 2020-05-27
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03273712
   Summary: This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
   Locations: University of Iowa Hospitals and Clinics, Iowa City, United States
----------------------------------------

5. Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
   NCT ID: NCT01327612
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced Solid Tumors; Carcinoid; Colorectal Cancer; Locally Advanced; Lymphoma; Metastatic Cancer; Non-Small Cell Lung Cancer; Sarcoma; Solid Tumors
   Intervention: Modified FOLFOX6; Conatumumab; Ganitumab; Bevacizumab
   Sponsor: Amgen
   Start Date: 2011-03-03
   Completion Date: 2020-02-05
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01327612
   Summary: The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.
   Locations: Research Site, Duarte, United States; Research Site, La Jolla, United States; Research Site, Denver, United States
              ... and 9 more locations
----------------------------------------

6. Cabozantinib and Nivolumab for Carcinoid Tumors
   NCT ID: NCT04197310
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumor; Carcinoid Tumor of GI System; Neuroendocrine Tumors
   Intervention: Nivolumab; Cabozantinib
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2019-12-26
   Completion Date: 2024-01-31
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04197310
   Summary: This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors.

- Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.
   Locations: Boston Medical Center, Boston, United States; Dana Farber Cancer Institute, Boston, United States
----------------------------------------

7. RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
   NCT ID: NCT02489903
   Status: COMPLETED
   Phase: PHASE2
   Condition: Small Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Neuroendocrine Tumors; Ovarian Epithelial Cancer
   Intervention: RRx-001; Cisplatin; Etoposide; Carboplatin; Irinotecan; Vinorelbine; Doxil; Gemcitabine; Taxane; Paclitaxel; Nab-Paclitaxel; Pemetrexed
   Sponsor: EpicentRx, Inc.
   Start Date: 2015-06
   Completion Date: 2021-12-06
   Has Posted Results: True
   Publications Count: 2
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02489903
   Summary: This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-...
   Locations: Stanford University, Palo Alto, United States; VA Connecticut Cancer Center, West Haven, United States; Memorial Hospital of South Bend, South Bend, United States
              ... and 7 more locations
----------------------------------------

8. Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
   NCT ID: NCT01782443
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumor
   Intervention: Ziv-aflibercept
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2013-02-13
   Completion Date: 2021-12-26
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01782443
   Summary: This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug, Ziv-aflibercept, is being studied. It also means that the FDA has not yet approv...
   Locations: Massachusetts General Hospital, Boston, United States; Brigham and Women's Hospital, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
----------------------------------------

9. Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
   NCT ID: NCT03896503
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Extensive Stage Lung Small Cell Carcinoma; Extrapulmonary Small Cell Neuroendocrine Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma
   Intervention: Berzosertib; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Topotecan Hydrochloride
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2019-12-30
   Completion Date: 2026-03-31
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03896503
   Summary: This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back (relapsed), or small cell cancer that arises from a site other than the ...
   Locations: Los Angeles General Medical Center, Los Angeles, United States; USC / Norris Comprehensive Cancer Center, Los Angeles, United States; USC Norris Oncology/Hematology-Newport Beach, Newport Beach, United States
              ... and 30 more locations
----------------------------------------

10. Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
   NCT ID: NCT03136055
   Status: COMPLETED
   Phase: PHASE2
   Condition: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
   Intervention: Pembrolizumab; Irinotecan; Paclitaxel
   Sponsor: University of California, San Francisco
   Start Date: 2017-06-20
   Completion Date: 2021-10-31
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03136055
   Summary: This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
   Locations: University of California, San Francisco, San Francisco, United States; Dana Farber Cancer Institute, Boston, United States; Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

11. AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
   NCT ID: NCT03453489
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Syndrome; Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
   Intervention: Carbon C 11 Alpha-methyltryptophan; Laboratory Biomarker Analysis; Positron Emission Tomography; Telotristat Etiprate
   Sponsor: Barbara Ann Karmanos Cancer Institute
   Start Date: 2018-06-20
   Completion Date: 2020-10-15
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03453489
   Summary: This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the gr...
   Locations: Wayne State University/Karmanos Cancer Institute, Detroit, United States
----------------------------------------

12. Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
   NCT ID: NCT02441062
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma; Medulloblastoma
   Intervention: 68Ga-DOTATOC PET/CT
   Sponsor: Sue O'Dorisio
   Start Date: 2015-09
   Completion Date: 2020-01-20
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02441062
   Summary: Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.

The purpose of this research study is to see if the tumor can be identified using a special proced...
   Locations: University of Iowa Hospitals and Clinics, Iowa City, United States
----------------------------------------

13. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
   NCT ID: NCT03375320
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm
   Intervention: Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2018-10-26
   Completion Date: 2025-11-22
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03375320
   Summary: This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherap...
   Locations: Katmai Oncology Group, Anchorage, United States; Kingman Regional Medical Center, Kingman, United States; Mayo Clinic Hospital in Arizona, Phoenix, United States
              ... and 433 more locations
----------------------------------------

14. A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
   NCT ID: NCT02795858
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumors
   Intervention: Ramucirumab; Somatostatin Analog
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2016-06-14
   Completion Date: 2023-12-31
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02795858
   Summary: This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
   Locations: Massachusetts General Hospital, Boston, United States; Dana Farber Cancer Institute, Boston, United States
----------------------------------------

15. A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
   NCT ID: NCT03070301
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: LEE011; everolimus
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2017-02-27
   Completion Date: 2024-01-31
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03070301
   Summary: The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
   Locations: Massachusetts General Hospital, Boston, United States; Dana Farber Cancer Institute, Boston, United States; Beth Israel Deaconess Medical Center, Boston, United States
              ... and 2 more locations
----------------------------------------

16. Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
   NCT ID: NCT04400474
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumor; Anaplastic Thyroid Cancer; Adenocarcinoma; Pheochromocytoma; Paraganglioma
   Intervention: Cabozantinib 40 mg
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2020-10-07
   Completion Date: 2023-12-15
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04400474
   Summary: CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system.

The primary objective is to assess the efficacy of cabozantinib plus atezolizumab combination by means of radiological objective response rate (ORR) evaluated followin...
   Locations: Hospital Germans Trias i Pujol - ICO Badalona, Badalona, Spain; Hospital Duran i Reynals - ICO L'Hospitalet, L'Hospitalet de Llobregat, Spain; Hospital General Universitario Elche, Alicante, Spain
              ... and 12 more locations
----------------------------------------

17. Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
   NCT ID: NCT04452292
   Status: COMPLETED
   Phase: NA
   Condition: Large-Cell Neuroendocrine Carcinoma
   Intervention: Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma; Treatment for Small Cell Lung Cancer
   Sponsor: Charles Kunos
   Start Date: 2021-09-14
   Completion Date: 2023-03-14
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04452292
   Summary: PRECISION-NEC is a single-center, open-label, pilot feasibility study of molecularly defined subtypes of metastatic high-grade neuroendocrine carcinoma (HG-NEC). The hypothesis is that HG-NEC (excluding small cell carcinoma) can be segregated based on mutational analysis and that next generation seq...
   Locations: Markey Cancer Center, University of Kentucky, Lexington, United States
----------------------------------------

18. Dual-Tracer Theranostic PET
   NCT ID: NCT05680675
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors; Prostate Cancer
   Intervention: Single-Tracer FDG PET/CT Exam; Single-Tracer Cu64-DOTATATE PET/CT Exam; Single-Tracer Ga68-DOTATATE PET/CT Exam; Single-Tracer PSMA PET/CT Exam
   Sponsor: University of Utah
   Start Date: 2022-12-08
   Completion Date: 2024-06-04
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05680675
   Summary: This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging techniques and processing algorithms for these tracer pairs.
   Locations: Huntsman Cancer Institute, Salt Lake City, United States
----------------------------------------

19. Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
   NCT ID: NCT04986085
   Status: COMPLETED
   Phase: N/A
   Condition: Gastroenteropancreatic Neuroendocrine Tumor
   Intervention: 
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2021-02-24
   Completion Date: 2024-02-23
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04986085
   Summary: It is well known that the prevalence of malnutrition or risk of malnutrition in cancer patients is high, as well as its impact on different parameters such as hospitalization, survival or response to certain treatments. In patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET), due t...
   Locations: Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain; Hospital Universitario Vall d´Hebron, Barcelona, Spain; Hospital Universitario Reina Sofia, Córdoba, Spain
              ... and 13 more locations
----------------------------------------

20. Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
   NCT ID: NCT01466036
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
   Intervention: Cabozantinib
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2012-07
   Completion Date: 2023-12
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01466036
   Summary: Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantini...
   Locations: Massachusetts General Hospital, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
----------------------------------------

21. Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
   NCT ID: NCT02609737
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: PET/CT Imaging; 68Ga-DOTA-JR11; 177Lu-DOTA-JR11
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2015-11-13
   Completion Date: 2020-12-10
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02609737
   Summary: This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

22. Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
   NCT ID: NCT04524442
   Status: COMPLETED
   Phase: PHASE4
   Condition: Gastroenteropancreatic Neuroendocrine Tumors
   Intervention: arginine/lysine
   Sponsor: Advanced Accelerator Applications
   Start Date: 2021-01-25
   Completion Date: 2023-11-18
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04524442
   Summary: The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post start of infusion compared to baseline.
   Locations: Istituto Europeo di Oncologia, Milan, Italy; Erasmus University Medical Center, Rotterdam, Netherlands; Gammed-Centrum Diagnostyczno-Lecznicze, Warsaw, Poland
              ... and 4 more locations
----------------------------------------

23. Phase 2 Study of ONC201 in Neuroendocrine Tumors
   NCT ID: NCT03034200
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Neuroendocrine Tumor; Metastatic Neuroendocrine Tumor
   Intervention: ONC201
   Sponsor: Peter Anderson
   Start Date: 2017-08-02
   Completion Date: 2023-05-19
   Has Posted Results: True
   Publications Count: 8
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03034200
   Summary: The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocyt...
   Locations: Cleveland Clinic Pediatric and Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, United States
----------------------------------------

24. The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
   NCT ID: NCT02282059
   Status: COMPLETED
   Phase: N/A
   Condition: Pancreatic Neuroendocrine Tumors
   Intervention: sunitinib
   Sponsor: Pfizer
   Start Date: 2014-12-12
   Completion Date: 2022-12-12
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02282059
   Summary: This study is a multi-center, prospective, non-interventional (NI) study evaluating the safety and efficacy of sunitinib in Chinese patients with progressive, unresectable, advanced or metastatic well-differentiated, pancreatic neuroendocrine tumors(pNET). 100 adults with progressive advanced or met...
   Locations: Oncology Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, China; Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China; SUN Yat-Sen University Cancer Center, Guangzhou, China
              ... and 21 more locations
----------------------------------------

25. Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
   NCT ID: NCT02893917
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma With Neuroendocrine Differentiation; Stage IV Prostate Adenocarcinoma AJCC v7
   Intervention: Cediranib; Olaparib
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2017-08-11
   Completion Date: 2026-06-18
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02893917
   Summary: This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can ...
   Locations: UC San Diego Moores Cancer Center, La Jolla, United States; University of California Davis Comprehensive Cancer Center, Sacramento, United States; UC San Diego Medical Center - Hillcrest, San Diego, United States
              ... and 13 more locations
----------------------------------------

26. Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
   NCT ID: NCT03972488
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Gastro-enteropancreatic Neuroendocrine Tumor
   Intervention: Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable
   Sponsor: Advanced Accelerator Applications
   Start Date: 2020-01-08
   Completion Date: 2027-10-29
   Has Posted Results: True
   Publications Count: 2
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03972488
   Summary: The aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to tr...
   Locations: Yale Cancer Center, New Haven, United States; USF - H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States; University of Iowa Hospitals and Clinics - Oncology, Iowa City, United States
              ... and 37 more locations
----------------------------------------

27. Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
   NCT ID: NCT01794793
   Status: COMPLETED
   Phase: PHASE4
   Condition: Cushing's Disease; Acromegaly; Neuroendocrine Tumors; Pituitary Tumors; Ectopic ACTH Secreting (EAS) Tumors; Dumping Syndrome; Prostate Cancer; Melanoma Negative for bRAF; Melanoma Negative for nRAS
   Intervention: Pasireotide; Cabergoline; Pasireotide LAR
   Sponsor: RECORDATI GROUP
   Start Date: 2013-06-10
   Completion Date: 2023-07-25
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01794793
   Summary: The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
   Locations: Ximed Research SC - SOM230B2412, La Jolla, United States; Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, United States; Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, United States
              ... and 91 more locations
----------------------------------------

28. Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
   NCT ID: NCT03223428
   Status: COMPLETED
   Phase: N/A
   Condition: Carcinoid Syndrome
   Intervention: Xermelo
   Sponsor: TerSera Therapeutics LLC
   Start Date: 2017-06-22
   Completion Date: 2022-01-14
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03223428
   Summary: The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).
   Locations: RTI-HS, Research Triangle Park, United States
----------------------------------------

29. Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
   NCT ID: NCT01253161
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Carcinoid Tumors
   Intervention: Pasireotide Long Acting Release (LAR)
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2011-02-01
   Completion Date: 2023-03-02
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01253161
   Summary: The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied. The patient's physical state, changes in the size of the tumor, and laboratory findings taken w...
   Locations: Stanford Cancer Institute, Stanford, United States; H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
----------------------------------------

30. 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
   NCT ID: NCT01563354
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma of the Lung and Thymus
   Intervention: Pasireotide LAR; Everolimus; Pasireotide LAR and Everolimus Combination
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2013-08-16
   Completion Date: 2020-02-10
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01563354
   Summary: This was a multicenter, randomized, phase II study evaluating Everolimus or Pasireotide LAR alone or in combination in adult patients with advanced (unresectable or metastatic) neuroendocrine carcinoma of the lung and thymus
   Locations: Novartis Investigative Site, Aarhus, Denmark; Novartis Investigative Site, Copenhagen N, Denmark; Novartis Investigative Site, Toulouse, France
              ... and 33 more locations
----------------------------------------

31. Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
   NCT ID: NCT04711135
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Gastroenteropancreatic Neuroendocrine Tumors; Pheochromocytoma; Paraganglioma
   Intervention: Lutetium [177Lu] oxodotreotide/dotatate
   Sponsor: Advanced Accelerator Applications
   Start Date: 2022-08-31
   Completion Date: 2034-05-07
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04711135
   Summary: This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL ...
   Locations: University of Kentucky, Lexington, United States; Cincinnati Children's Hospital, Cincinnati, United States; Children's Hospital of Philadelphia, Philadelphia, United States
              ... and 4 more locations
----------------------------------------

32. A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
   NCT ID: NCT03289741
   Status: COMPLETED
   Phase: PHASE4
   Condition: Neuroendocrine Tumors
   Intervention: Octreotide; LAR Lanreotide; Questionnaires
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2017-09-19
   Completion Date: 2023-04-10
   Has Posted Results: True
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03289741
   Summary: This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.
   Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, United States; Memorial Sloan Kettering Monmouth, Middletown, United States; Memorial Sloan Kettering Bergen, Montvale, United States
              ... and 4 more locations
----------------------------------------

33. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
   NCT ID: NCT02893930
   Status: COMPLETED
   Phase: PHASE2
   Condition: Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2; Refractory Pancreatic Neuroendocrine Carcinoma
   Intervention: Sapanisertib
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2017-04-28
   Completion Date: 2022-12-21
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02893930
   Summary: This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or s...
   Locations: Mayo Clinic Hospital in Arizona, Phoenix, United States; Mayo Clinic in Arizona, Scottsdale, United States; CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, United States
              ... and 402 more locations
----------------------------------------

34. Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
   NCT ID: NCT03980925
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Neuroendocrine Neoplasm; Gastroenteropancreatic Neuroendocrine Tumor
   Intervention: Nivolumab; Carboplatin; Etoposide
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2019-10-11
   Completion Date: 2023-06-09
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03980925
   Summary: This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced G3 NENs of the GEP tract or of UK origin.
   Locations: Institut Català d'Oncologia Badalona, Badalona, Spain; Institut Català d'Oncologia l'Hospitalet, Hospitalet de Llobregat, Spain; Vall d'Hebron University Hospital, Barcelona, Spain
              ... and 9 more locations
----------------------------------------

35. Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
   NCT ID: NCT02259725
   Status: COMPLETED
   Phase: PHASE2
   Condition: Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma
   Intervention: regorafenib; laboratory biomarker analysis
   Sponsor: University of Southern California
   Start Date: 2016-08-16
   Completion Date: 2020-08-20
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02259725
   Summary: This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
   Locations: Mayo Clinic in Arizona, Scottsdale, United States; USC Norris Comprehensive Cancer Center, Los Angeles, United States; Hoag Memorial Hospital Presbyterian, Newport Beach, United States
              ... and 2 more locations
----------------------------------------

36. Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
   NCT ID: NCT02842749
   Status: COMPLETED
   Phase: PHASE4
   Condition: Pancreatic Neuroendocrine Tumors
   Intervention: everolimus
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2016-03-14
   Completion Date: 2024-02-22
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02842749
   Summary: To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
   Locations: Novartis Investigative Site, Shanghai, China; Novartis Investigative Site, Beijing, China; Novartis Investigative Site, Beijing, China
              ... and 2 more locations
----------------------------------------

37. Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor
   NCT ID: NCT02246127
   Status: COMPLETED
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: Drug: Everolimus; STZ-5FU
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2014-10-27
   Completion Date: 2021-07-12
   Has Posted Results: True
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02246127
   Summary: The purpose of this study is to compare streptozotocin (STZ) vs everolimus as first line treatment for advanced pNET and to elucidate which sequence of STZ based chemotherapy and the mammalian Target of Rapamycin (mTOR) inhibitor, everolimus, gives better results in terms of second Progression Free ...
   Locations: Aarhus Aarhus University Hospital NET Centre (AUH-NET), Aarhus, Denmark; Rigshospitalet NET CoE, University of Copenhagen, Copenhagen, Denmark; Odense University Hospital, Odense, Denmark
              ... and 34 more locations
----------------------------------------

